June 26 - 27, 2017
Princeton, NJ

Media Center

Fast Track Your Attendance

Past Attendee Snapshot

Chief Financial Officers, Senior Vice Presidents, Directors and other industry executives attended the summit last year. Take a look at last year's Attendee Snapshot to see which of your peers attended and who you are likely to see at this year's summit.

Registration Form

Download the Registration Form and secure your spot today.

Convince Your Boss Letter

Present your boss with this customizable letter detailing the reasons why you should attend the summit and you'll be sure to receive permission to join us.

Exclusive Content

Gross Negligence: The G2N Disconnects Which Cripple Your Business

Though gross-to-net accounting is considered to be a critical accounting obligation both from a compliance and strategic planning perspective, at many organizations it is marred by clunky and inefficient processes. We took a look at some of the key disconnects in GTN to help you get your house in order in advance of the Summit.

Go With the Flow: Forecasting, Analytics, and You

It’s no secret that successful marketing and sales campaigns require both art and science to execute. You’re already aware that analytics, once considered a luxury, are now a necessity, but are you leveraging them to their maximum potential?

Are You in Control of Your Accruals Processes?

Are you debating how to apply automation to your manual accruals operations? We spoke with Roxana Santiago, Global Finance SOX Manager at Pfizer, and speaker at the summit, about whether automating accruals grants greater control and lower risk – and whether it’s even feasible in 2017.

11 GTN Analytics Implementation Best Practices

Matthew J. Pellegrini the Director of Revenue Management at Amneal Pharmaceuticals discussed with us some of the best practices learned during the implementation of gross to net (GTN) analytics to drive bottom-line.

Key Considerations & Steps to Optimize your GTN Processes

We sat down with experts Luyan Li, Controller and Treasurer at Medac Pharma, Inc. and John Shakow, Partner at King & Spalding. They discuss with us some important information for effectively developing and leveraging GTN forecasts, and the impact of the new AMP rule. Both will also be speaking even further at the summit this June on these topics.

Presentations

Gross to Net Principles

This presentation, courtesy of Deloitte, goes into types of pricing adjustments, the G2N estimation process, updates on hot G2N topics, sales returns, and more!

Chargeback 101

In this presentation, learn the steps to understanding chargeback and how it impacts your bottom line. Topics include understanding the relationship between chargeback for commercial vs. government pricing and contracting departments, overcoming disputes and deductions by your wholesaler partners, and more.

Leverage Customer Data to Make Improved Accrual Decisions

In this presentation, learn how to enable interdepartmental collaboration to ensure all relevant customer data is efficiently and accurately collected, and how to develop strategic forecasts that are capable of driving aggressive business growth.

GTN Forecasting, Accruals and Analytics

In this presentation, learn more about some of the key challenges in GTN and how to successfully solve them to mitigate risk and drive good business decisions.

Commercial Analytics & How They Can Impact the Financial Close

In this presentation, learn the fundamentals to preparing for the close process, including how using data and discussion can drive contracting, forecasting complexity, and the data requirements for contracting and forecasting results before you start the close process.

White Papers

Finance Transformation in the Pharmaceutical Industry

This whitepaper, courtesy of RSM, tackles the increasingly complex pharmaceutical business model from the R&D and pre-clinical phase, through FDA approval and commercialization.

The Economic Footprint of the Pharmaceutical Industry – Regional Breakdown and Differentiation between Originators and Generics

This study independently conducted by WifOR reveals how the pharmaceutical industry, one of the world’s largest industries, plays a major role in boosting the global economy across regions. This study was commissioned by the IFPMA and aims to refine the study on ‘Measuring the economic footprint of the pharmaceutical industry – Feasibility study’ that examined for the first time the global economic importance of the pharma industry.

Articles

Social Security Finance Bill 2016 in France: French Government Looks To Make 50% Of Healthcare Savings Through Drug Price Cuts

With there being a 12.8 million Euro deficit in France’s 2015 budget, the French government announced on 24th September plans for the Projet de Loi de Financement de la Sécurité Sociale 2016 (PLFSS; Social Security Finance Bill 2016). For the second consecutive year, the PFLSS cost-containment measures include a heavy focus on drug expenditure as part of the...

Pharma & Biotech’s Merger Fever: The Highlights

In 2015, the pharma and biotech industry was diagnosed with what was coined as merger fever. Industry analysts state that the first half of 2015 soared past 2014’s grand total of $162 billion, with the total value of pharma M&As in the first two quarters of 2015 sitting at $221 billion. Read more!